Veru company info

What does Veru do?
Veru (NASDAQ:VERU) focuses on developing novel medicines for the management of breast cancer and severe COVID-19. With a dedicated team working steadfastly, their projects range from early-stage research to late-stage clinical trials aimed at addressing unmet medical needs. Furthermore, Veru is traded on the NASDAQ under the symbol VERU. The company's objective is not only to advance the treatment options available for breast cancer and serious COVID-19 cases but also to enhance patient outcomes through innovative therapeutic solutions. Their commitment to research and development in these critical areas underscores their dedication to improving health and making a meaningful impact in the lives of patients worldwide.
Veru company media
Company Snapshot

Is Veru a public or private company?

key
Ownership
Public

How many people does Veru employ?

people
Employees
189

What sector is Veru in?

pie chart
Sector
Consumer Staples

Where is the head office for Veru?

location pin
Head Office
Miami, United States

What year was Veru founded?

founded flag
Year Founded
1971
What does Veru specialise in?
/Oncology Therapeutics /Women's Health /Sexual Health /Pharmaceutical Development /Clinical Trials /Breast Cancer Treatment

What are the products and/or services of Veru?

Overview of Veru offerings
Development of VERU-111, an oral selective antitubulin agent targeting metastatic breast cancer and COVID-19 associated ARDS.
Commercialization of FC2 Female Condom, designed for dual protection against unwanted pregnancies and sexually transmitted infections.
Progression of Enobosarm, a novel oral androgen receptor targeting agent, for androgen receptor positive metastatic breast cancer.
Advancement of VERU-100, a peptide formulation for androgen deprivation therapy in advanced prostate cancer treatment.
Exploration of zuclomiphene citrate, aimed at treating hot flashes in men undergoing hormone therapy for prostate cancer.
Marketing of TADFIN, a combination therapy for benign prostatic hyperplasia and erectile dysfunction.

Who is in the executive team of Veru?

Veru leadership team
  • Dr. Mitchell S. Steiner F.A.C.S., M.D.
    Dr. Mitchell S. Steiner F.A.C.S., M.D.
    Chairman, President & CEO
  • Dr. Harry  Fisch F.A.C.S., M.D.
    Dr. Harry Fisch F.A.C.S., M.D.
    Vice Chairman & Chief Corporate Officer
  • Ms. Michele  Greco
    Ms. Michele Greco
    CFO & Chief Administrative Officer
  • Dr. K. Gary Barnette Ph.D.
    Dr. K. Gary Barnette Ph.D.
    Chief Scientific Officer
  • Mr. Samuel  Fisch
    Mr. Samuel Fisch
    Executive Director of Investor Relations & Corporate Communications
  • Mr. Michael J. Purvis
    Mr. Michael J. Purvis
    Executive VP, General Counsel & Corporate Strategy and Secretary
  • Mr. Kevin J. Gilbert CPA, J.D.
    Mr. Kevin J. Gilbert CPA, J.D.
    Executive Vice President of Corporate Development
  • Mr. Martin  Tayler
    Mr. Martin Tayler
    Executive Vice President of FC2 Global Operations